GlaxoSmithKline Pakistan (KAR:GLAXO) Cash-to-Debt : 37.43 (As of Dec. 2024)

View and export this data going back to 1953. Start your Free Trial

What is GlaxoSmithKline Pakistan Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. GlaxoSmithKline Pakistan's cash to debt ratio for the quarter that ended in Dec. 2024 was 37.43.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, GlaxoSmithKline Pakistan could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

The historical rank and industry rank for GlaxoSmithKline Pakistan's Cash-to-Debt or its related term are showing as below:

KAR:GLAXO' s Cash-to-Debt Range Over the Past 10 Years
Min: 23.66 Med: 158.25 Max: No Debt
Current: 37.43

During the past 13 years, GlaxoSmithKline Pakistan's highest Cash to Debt Ratio was No Debt. The lowest was 23.66. And the median was 158.25.

KAR:GLAXO's Cash-to-Debt is ranked better than
84.06% of 1004 companies
in the Drug Manufacturers industry
Industry Median: 1.02 vs KAR:GLAXO: 37.43

GlaxoSmithKline Pakistan Cash-to-Debt Historical Data

The historical data trend for GlaxoSmithKline Pakistan's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

GlaxoSmithKline Pakistan Cash-to-Debt Chart

GlaxoSmithKline Pakistan Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash-to-Debt

Get a 7-Day Free Trial

153.85

162.66

76.78

23.66

37.43

GlaxoSmithKline Pakistan Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash-to-Debt	Get a 7-Day Free Trial															23.66	20.07	23.68	39.84	37.43

Competitive Comparison of GlaxoSmithKline Pakistan's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, GlaxoSmithKline Pakistan's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GlaxoSmithKline Pakistan's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pakistan's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where GlaxoSmithKline Pakistan's Cash-to-Debt falls into.

Save Embed

;

Save Embed

;

GlaxoSmithKline Pakistan Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

GlaxoSmithKline Pakistan's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	6498.947	/	(27.894	+	145.758)
	=	37.43

GlaxoSmithKline Pakistan's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	6498.947	/	(27.894	+	145.758)
	=	37.43

GlaxoSmithKline Pakistan (KAR:GLAXO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

GlaxoSmithKline Pakistan Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Pakistan's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

GlaxoSmithKline Pakistan Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Pakistan Ltd (KAR:GLAXO) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

35, Dockyard Road, West Wharf, Karachi, PAK, 74000

Website

https://www.pk.gsk.com

GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company derives maximum revenue from the Pharmaceuticals segment.

GlaxoSmithKline Pakistan Headlines

No Headlines